Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $2.6 million.

  • Lyell Immunopharma's Depreciation & Amortization (CF) fell 45.17% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 27.94%. This contributed to the annual value of $19.6 million for FY2024, which is 3.06% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Depreciation & Amortization (CF) is $2.6 million, which was down 18.15% from $3.1 million recorded in Q2 2025.
  • Lyell Immunopharma's Depreciation & Amortization (CF)'s 5-year high stood at $5.1 million during Q3 2023, with a 5-year trough of $2.0 million in Q1 2021.
  • For the 3-year period, Lyell Immunopharma's Depreciation & Amortization (CF) averaged around $4.5 million, with its median value being $5.0 million (2024).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 270.56% in 2021, then crashed by 45.17% in 2025.
  • Over the past 5 years, Lyell Immunopharma's Depreciation & Amortization (CF) (Quarterly) stood at $4.6 million in 2021, then rose by 10.43% to $5.0 million in 2022, then rose by 0.32% to $5.1 million in 2023, then dropped by 0.61% to $5.0 million in 2024, then tumbled by 45.17% to $2.6 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.6 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.4 million for Q1 2025.